Cholangiocarcinoma
411
88
115
136
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
48 trials with published results (12%)
Research Maturity
136 completed trials (33% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.7%
52 terminated out of 411 trials
72.3%
-14.2% vs benchmark
5%
19 trials in Phase 3/4
35%
48 of 136 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 136 completed trials
Clinical Trials (411)
Evaluation of Skin Tests in Biotherapy Allergies
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Liver Cancer Registry Platform
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Trop2-targeted immunoPET Imaging of Solid Tumors
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)